The effect of yoghurt and soya yoghurt containing Bifidobacterium lactis Bb-12 or B. longum Bb-46 on Ehrlich ascites tumour cell proliferation was investigated in vitro and in vivo. Tumour cells were incubated with B. lactis Bb-12 or B. longum Bb-46 cultivated in de Mann Rogosa Sharpe (MRS) broth medium, or with their centrifuged supernatant fractions or sediments, for 2 h at 378C. Treatment resulted in the inhibition of tumour cell proliferation by 85·42 (SD 0·78) and 85·10 (SD 1·28) % by intact micro-organisms, 77·61 (SD 0·29) and 71·43 (SD 1·75) % by their supernatant fractions, but only 4·00 (SD 0·19) and 9·09 (SD 1·24) % by the two sedimented bacteria, respectively. The incubation of tumour cells with yoghurt and soya yoghurt containing Bb-12 for 2 h resulted in 83·01 (SD 0·11) and 88·23 (SD 0·06) % inhibition, respectively, while it was 83·82 (SD 0·24) and 86·36 (SD 0·06) %, respectively for the same products containing Bb-46. Corresponding values for plain yoghurt and soya milk (without bifidobacteria) were 32·81 (SD 0·14) and 5·55 (SD 0·12) %, respectively. The differences between yoghurt or soya yoghurt containing Bb-12 or Bb-46 and plain yoghurt, soya milk or control treatments were statistically significant (n 3; P, 0·05). Female Swiss albino mice were injected intraperitoneally with the same tumour cells. The lifespan of mice fed diets supplemented with yoghurt or soya yoghurt containing Bb-12 or Bb-46 was prolonged by 16, 23, 34 and 39 %, respectively compared with that of the positive control group (n 6; P, 0·05). The lifespan of groups fed plain yoghurt or soya milk was prolonged by 15 and 8 %, respectively. Prolongation of lifespan was positively correlated with faeces bifidobacterial count in the groups fed yoghurt or soya yoghurt containing bifidobacteria (r 0·917; P, 0·05).
Functional foods hold great promise for human nutrition, but relatively little objective evidence exists for their beneficial effects. Since 1986, yoghurt cultures have been supplemented or replaced by Bifidobacterium spp. with the intention of enhancing their therapeutic value (Kailaspathy & Rybka, 1997) . Most probiotic foods are derived from milk fermentation and the possibility of using other protein-rich substrates such as soya milk to make such foods has not been adequately considered. The potential role of dietary soya in the prevention and treatment of chronic diseases, in particular heart disease and cancer, has been recognised for a long time (Nagata et al. 1982; Anthony et al. 1996) . Recently, soya yoghurt has been prepared by the fermentation of soya milk using lactic acid bacteria or bifidobacteria Chou & Hou, 2000) .
Although various studies have addressed the health effects of yoghurt, relatively little is known about the potential anti-tumour effects of yoghurt and soya yoghurt containing bifidobacteria. Therefore, the aim of the present study was to explore the possible anti-tumour activity exerted by yoghurt and soya yoghurt containing bifidobacteria both in vitro and in vivo.
Materials and methods

Preparation of yoghurt
Low-fat buffalo milk (1·5 %) was inoculated with a 3 % (v/v) liquid culture of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus salivarius subsp. thermophilus (Chr. Hansen Laboratories, Copenhagen, Denmark), and then divided into three portions. No bifidobacteria were added to the first portion (plain yoghurt). To the second portion, a 0·07 % (w/v) standardised freeze-dried culture of Bifidobacterium lactis Bb-12 was added. To the third portion, a 0·07 % (w/v) standardised freeze-dried culture of B. longum Bb-46 was added. The two strains were obtained from Chr. Hansen Laboratories (Copenhagen, Denmark). After incubation the yoghurts were stored at 4^18C.
Fresh and non-beany-flavour soya milk was prepared according to Tanteeratarm et al. (1993) as described by Abd . Soya yoghurt was prepared from soya milk using 0·07 % (w/v) B. lactis Bb-12 or B. longum Bb-46 according to El-Sayed et al. (1998) .
Ehrlich ascites tumour cells were obtained from the National Cancer Institute, Cairo University and maintained by weekly intraperitoneal injection of 0·1 ml ascitic fluid in female Swiss albino mice.
Test materials
The test materials were bifidobacterial cultures in de Mann Rogosa Sharpe (MRS) medium and their centrifuged fractions (at 11 400 g and 58C for 15 min) as well as six different products: plain yoghurt, yoghurt containing Bb-12, yoghurt containing Bb-46, soya milk, soya yoghurt containing Bb-12 and soya yoghurt containing Bb-46.
Bacterial quantification
Bacterial counts of S. salivarius subsp. thermophilus and L. delbrueckii subsp. bulgaricus in yoghurt were determined according to Lee et al. (1973) , in which the yoghurt sample was added to Lee's agar and incubated at 438C for 3 d. Bifidobacteria were enumerated in soya yoghurt by a poured plate method using Lactobacilli MRS-agar medium as described by Samona & Robinson (1991) . Bifidobacteria were enumerated in yoghurt containing Bb-12 or Bb-46 according to the method of Dinakar & Mistry (1994) , in which a mixture of antibiotics, including 2 g paromomycin sulfate, 0·3 g nalidixic acid, and 60 g lithium chloride, was dissolved in 1 litre distilled water, filter-sterilised (0·2 mm) and stored at 48C until use. The antibiotic mixture (5 ml) was added to 100 ml MRS-agar medium. L-Cysteine-HCl 0·5 % (Sigma Chemical Co., St Louis, MO, USA) was also added to decrease the redox potential of the medium. Plates were incubated at 378C for 48 h anaerobically. The viable counts of yoghurt cultures and bifidobacteria in the test products are shown in Table 1 .
In vitro determination of anti-tumour activity At 7 d after the injection of tumour cells, 2 £ 10 6 Ehrlich ascites tumour cells were taken from the peritoneal cavity of the mice and mixed with the RPMI 1640 medium, then inoculated with 10 ml of each test material for 2 and 24 h at 378C. Each test material was added to the tumour cells with and without heating to 858C, followed by cooling to 378C. After incubation, 30 ml cell suspension were mixed with 5 ml trypan blue dye. The number of dead tumour cells was measured according to the method of Bennett et al. (1976) using a haemocytometer slide under microscope examination.
In vivo determination of anti-tumour activity
The female Swiss albino mice were housed in cages with a screen bottom in a temperature-and humidity-controlled room. All animals were kept under normal healthy conditions and fed a basal diet (Table 2 ) for 1 week. After this adaptation period, the mice were divided randomly into eight experimental groups each of six animals. Two groups received the basal diet throughout the experimental period (control groups), the other six groups were fed a basal diet supplemented with plain yoghurt, yoghurt Bb-12, yoghurt Bb-46, soya milk, soya yoghurt Bb-12 or soya yoghurt Bb-46 throughout the experimental period. After 3 weeks, these six groups and one of the two control groups were injected intraperitoneally with 2 £ 10 6 Ehrlich asites tumour cells. The injected control group served as a positive control, while the other control group without injection served as a negative control. The mice were allowed free access to the experimental diet and water. Every 3 d, faeces were collected from each mouse and kept frozen until analysis. Whenever a mouse died the time of its death was recorded immediately. Faecal bifidobacteria were quantified by a poured plate method on Lactobacilli MRS-agar medium as described by Chen et al. (1999) .
Statistical analysis
Data are presented as means and standard deviations. The significant differences among treatments (groups) were evaluated using the general linear model procedure of SAS (1993; SAS Institute, Inc., Cary, NC, USA) to analyse the biological examination data by least significant difference at P, 0·05 (SAS Institute, Inc. 1990). 
Results
In vitro determination of anti-tumour activity
Effect of bifidobacteria cultivated in MRS broth medium and its centrifuged fractions. B. lactis Bb-12 and B. longum Bb-46 cultivated in MRS broth medium and added at 0·07 % (w/v) inhibited tumour cell proliferation by 85·42 and 94·74 % and by 85·10 and 94·00 % after 2 and 24 h incubation, whereas their supernatant fractions inhibited by 77·61 and 83·33 %, and by 71·43 and 88·06 %, respectively (Table 3) . In contrast, their sedimented fractions inhibited by only 4·00 and 16·07 %, and by 9·09 and 11·11 %. Data in Table 3 showed that the differences between the test and control treatments after 2 and 24 h incubation were statistically significant (P, 0·05). Effect of bifidobacteria-supplemented yoghurts. The inhibitory effects of yoghurt and soya yoghurt containing Bb-12 and Bb-46 in comparison with plain yoghurt and soya milk with and without heating at 858C on the proliferation of tumour cells are presented in Table 4 . Yoghurt and soya yoghurt containing Bb-12 and Bb-46 caused 83-98 % cell death. Plain-yoghurt treatment caused 32·81 and 63·89 % cell death after 2 and 24 h incubation, respectively. Soya milk and control treatments caused only 5·55 and 6·82 % and 3·39 and 3·92 % cell death after 2 and 24 h incubation, respectively. The differences between yoghurt or soya yoghurt containing Bb-12 or Bb-46 and plain yoghurt, soya milk or control treatments were statistically significant (n 3; P, 0·05). The antitumour activity of all tested products markedly decreased upon heating at 858C as compared with that of nonheated products (Table 4 ).
In vivo determination of anti-tumour activity
The effect of feeding of the basal diet supplemented with yoghurt and soya yoghurt containing Bb-12 or Bb-46 on the lifespan and survival rate of the mice injected with Ehrlich ascites tumour cells is presented in Table 5 . The lifespan of mice fed the diets supplemented with soya yoghurt and yoghurt containing Bb-12 and Bb-46 was 39, 34, 16 and 23 % longer than those of the control group, respectively. The corresponding average prolongation of lifespan in the mice fed the diets containing plain yoghurt and soya milk was 15 and 8 %, respectively. Table 6 illustrates the faecal bifidobacterial viable count of the experimental mice groups during the 9 d feeding period. Faecal bifidobacterial counts in the groups fed yoghurt and soya yoghurt containing Bb-12 and Bb-46 ranged between 1·5 and 3·0 £ 10 4 colony-forming units/g at the end of the feeding period. In contrast, faecal bifidobacterial counts in the mice fed the diets containing soya milk and plain yoghurt were 3·2 and 2·1 £ 10 3 colonyforming units/g, respectively; counts were lower still in the negative and positive control groups, reaching only 1·0 and 1·5 £ 10 2 colony-forming units/g at the end of the feeding period, respectively.
The prolongation of lifespan was positively correlated with faecal bifidobacterial counts in the groups fed yoghurt and more particularly soya yoghurt containing bifidobacteria (r 0·917; P, 0·05). 
Discussion
The purpose of the present study was to find whether yoghurt and soya yoghurt containing Bifidobacterium spp. were effective in the inhibition of the proliferation of Ehrlich ascites tumour cells in vitro and in vivo and to compare their effects with those of plain yoghurt and soya milk. B. lactis Bb-12 and B. longum Bb-46 cultures in MRS broth medium exhibited the greatest inhibitory effect on the proliferation of tumour cells, followed by their centrifugal supernatant fractions, while the sediments showed the lowest effect. These findings suggest that the tumour-suppressing activity of bifidobacteria was present mainly in the supernatant fraction. This is in agreement with Biffi et al. (1997) , who reported that the inhibitory effect of bifidobacteria may be related to metabolites and cell-wall components (Sekine et al. 1994) . Similarly Kohwi et al. (1978 Kohwi et al. ( , 1982 found that an anti-tumour effect was associated with the cell wall and whole cells of B. infantis and the soluble fraction of S. thermophilus (Friend et al. 1982) .
Yoghurt and soya yoghurt containing Bb-12 and Bb-46 had a greater anti-proliferation effect than plain yoghurt, while soya milk and control treatments had a weaker effect. A similar trend has been reported by Biffi et al. (1997) , who found that the growth of MCF7 breast cancer cells was inhibited by cultured milk containing bifidobacteria. Baricault et al. (1995) found that L. hilveticus and Bifidobacterium were the most effective in decreasing the growth rate of HT-29 human colon cancer cells. The present data showed that the anti-tumour activity of all tested products decreased considerably after heating at 858C (Table 4) . These results are in agreement with the findings of De Simone et al. (1986) , Perdigon et al. (1995) and Pool-Zobel et al. (1996) .
All mice fed with the tested products showed prolonged survival compared with that of the positive control group (Table 5 ) but this increase was significant only in the case of the mice fed the diets supplemented with soya yoghurt containing Bb-12 or Bb-46. These results are in line with Takano et al. (1985) who found that the growth of Ehrlich ascites tumour cells was inhibited by 28 and 42 % in mice given yoghurt and cultured-milk diets compared with the control group, respectively. Friend et al. (1982) noticed a decrease in the occurrence of tumours by 25 -30 % when feeding mice with yoghurt. Reddy et al. (1983) found that the consumption of yoghurt reduces the number of tumours by 20-32 % in mice implanted with Ehrlich tumour cells. Shackelford et al. (1983) found a significant prolongation in the lifespan of mice infected with colon tumours when fed with yoghurt. B. longum, a lactic acid-producing bacterium present in the human colon, has also been demonstrated to inhibit colon tumour development in experimental animals (Reddy & Riverson, 1993; Abdelali et al. 1995; Singh et al. 1997) .
In the present study, there was a strong relationship between the bifidobacterial count in the tested products (Table 1 ) and its count in mice faeces (Table 5 ) and accordingly the intestinal flora in mice. The bifidobacterial count in the faeces of the mice fed soya yoghurt containing Bb-12 or Bb-46 was higher than for the mice fed yoghurt containing Bb-12 or Bb-46 as well as in the faeces of corresponding Tables 1 and 2. † At the end of the experiment (17 d), the mice in the negative control group were killed by diethyl ether inhalation. ‡ Survival rate (%) ¼ (mean life span of treated group/mean life span of positive control group) £ 100. § Mice injected with tumour cells and fed the basal diet. mice groups (Table 6 ). The higher bifidobacterial count in soya yoghurt might explain the increase in lifespan of the mice fed soya yoghurt containing Bb-12 or Bb-46 compared with the other groups (Table 5) . Fernandes & Shahani (1990) suggested that the anti-carcinogenic effect of bifidobacteria may be the result of direct removal of procarcinogens, indirect removal of procarcinogens, or activation of the body's immune system. Bifidobacteria can greatly reduce the mutagenicity of nitrosamines by removing the source of procarcinogens or the enzymes which lead to their formation (Hosono et al. 1990 ). Alternatively Perdigon et al. (1998) suggested that one of the mechanisms by which yoghurt containing bifidobacteria exerts anti-tumour activity is through its immunomodulator activity by reducing the inflammatory immune response, which was markedly increased when the carcinogen was administered. Such reduction of the inflammatory immune response by bifidobacteria has been proposed potentially to prevent cancer (Sekine et al. 1985 (Sekine et al. , 1994 Rafter, 1995) . These anticancer effects are due to immune enhancements by the cells, cell-wall components and extracellular components of bifidobacteria (Abdelali et al. 1995; Rice et al. 1995; Pool-Zobel et al. 1996; McCarthy et al. 1997; Ohta et al. 2000) .
In conclusion, both the in vitro and in vivo studies suggested that yoghurt and more particularly soya yoghurt containing large numbers of viable bifidobacteria may have anti-tumour effects. If such functional dairy foods that contain bifidobacteria have the same effect in human subjects they may have potential value in cancer prevention.
